Business
BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to initiate a patient data registry for the Rotarex™ Atherectomy System to measure real-world outcomes for patients with peripheral artery disease (PAD).
About this update from Becton, Dickinson And Company
[{"type":"text","content":"FRANKLIN LAKES, N.J., May 28, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to initiate a patient data registry for the Rotarex™ Atherectomy System to measure real-world outcomes for patients with peripheral artery disease (PAD).","length":324,"tagName":"p"},{"type":"image","alt":"BD announces plans to initiate a patient data registry for the Rotarex™ Atherectomy System to measure real-world outcomes for patients with peripheral artery disease (PAD).","displaySize":"","headline":null,"caption":"BD announces plans to initiate a patient data registry for the Rotarex™ Atherectomy System to measure real-world outcomes for patients with peripheral artery disease (PAD).","className":"","disableSlideshowImg":false,"size":{"original":{"width":356,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/1d26cb539a5c7d6538a906221e53d636"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4ZDhSf7cEiCcE6wJUZljKg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTc5MjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/1d26cb539a5c7d6538a906221e53d636","width":356,"height":400}},"href":"https://mma.prnewswire.com/media/2697201/Rotarex_Thrombectmy.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Known as "XTRACT," this prospective, multi-center, single-arm, post-market registry study will assess the clinical performance of the Rotarex™ Atherectomy System in the treatment of U.S. patients with PAD lesions. The XTRACT Registry is being led in partnership with Co-Principal Investigators, Dr. Prakash Krishnan, an interventional cardiologist, and Dr. Todd Berland, a vascular surgeon. The registry will enroll up to 600 patients at approximately 100 clinical sites across the United States, with the first patient enrollment expected later this year. Clinical follow-up evaluations will occur after 30 days, 6 months and 12 months post-procedure to assess safety and effectiveness of outcomes.","length":709,"tagName":"p"},{"type":"text","content":""This registry will provide valuable data to support clinical decision-making and enhance patient outcomes in the management of PAD," said Dr. Krishnan. "The Rotarex™ System has been extensively studied internationally, and we are excited to further evaluate its adaptabil...